|
PARD3B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.24299995138711E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.05339999945109E-07 |
| Normal-vs-Stage2 |
2.08599999999004E-05 |
| Normal-vs-Stage3 |
1.94489999993941E-07 |
| Normal-vs-Stage4 |
4.90580000001017E-06 |
| Stage1-vs-Stage2 |
5.274000E-01 |
| Stage1-vs-Stage3 |
5.400400E-01 |
| Stage1-vs-Stage4 |
5.345400E-01 |
| Stage2-vs-Stage3 |
8.630200E-01 |
| Stage2-vs-Stage4 |
9.794400E-01 |
| Stage3-vs-Stage4 |
8.815600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.68889999552624E-08 |
| Normal-vs-AfricanAmerican |
2.255700E-02 |
| Normal-vs-Asian |
3.88009999999772E-05 |
| Caucasian-vs-AfricanAmerican |
2.511400E-01 |
| Caucasian-vs-Asian |
7.520200E-01 |
| AfricanAmerican-vs-Asian |
2.264200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.71459965617282E-10 |
| Normal-vs-Female |
1.57779999954144E-07 |
| Male-vs-Female |
3.766500E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.94749999996125E-06 |
| Normal-vs-Age(41-60Yrs) |
8.78660000314113E-09 |
| Normal-vs-Age(61-80Yrs) |
1.16329999966247E-07 |
| Normal-vs-Age(81-100Yrs) |
7.342800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.624600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.457800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.733400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.943800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.838800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.628200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.922400E-02 |
| Classical-VS-Follicular |
6.01820000000197E-05 |
| Classical-VS-Other |
1.736190E-01 |
| Classical-VS-Normal |
4.12819999995317E-06 |
| Tall-VS-Follicular |
3.131800E-01 |
| Tall-VS-Other |
3.921200E-01 |
| Tall-VS-Normal |
1.65870000001789E-06 |
| Follicular-VS-Other |
7.909600E-01 |
| Follicular-VS-Normal |
8.89719964369817E-10 |
| Other-VS-Normal |
2.800700E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.53510004707869E-09 |
| Normal-vs-N1 |
3.617400E-04 |
| N0-vs-N1 |
4.843800E-01 |
|
|
